Improving the Benefit/Risk Ratio

  • Stanford Wessler

Abstract

Using the smallest effective dose of warfarin, clearly will diminish hemorrhage. But there are more than a dozen factors other than dose that can either favorably effect the benefit/risk ratio or tell the physician that he should or should not consider using warfarin in specific patient groups. Three of these factors, the prothrombin time, warfarin resistance, and drug-drug interactions, have already been commented upon at this symposium and so I shall discuss several other factors.

Keywords

Oral Anticoagulant Cerebral Hemorrhage Warfarin Therapy Prosthetic Heart Valve Anticoagulant Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Wessler, A Guide to Anticoagulant Therapy, American Heart Association, 1984.Google Scholar
  2. 2.
    S. Wessler, Is anticoagulant prophylaxis of cardiac emboli practical?, Geriatrics (in press).Google Scholar
  3. 3.
    J. G. Hall, R. M. Pauli, and K. M. Wilson, Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122(1980).PubMedCrossRefGoogle Scholar
  4. 4.
    R. A. O’Reilly, and P. M. Aggeler, Determination of the response to oral anticoagulant drugs in man. Pharmacol Rev 22:35, 1980.Google Scholar
  5. 5.
    K. Fries, F. E. Konig, and T. Reich, Einfluss der Marcoumar-Therapie bei voll gestillten kindern, Schweiz Med Wochen Schr, 87:615(1957).Google Scholar
  6. 6.
    E. Marciniak, and J. P. Gockerman, Heparin-induced decrease in circulating antithrombin III, Lancet 2:581(1977).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Wessler, S. N. Gitel, H. Bank, U. Martinowitz, and R. C. Stephenson, An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits, Thromb Haemost 40:486(1978).Google Scholar
  8. 8.
    J. G. Domenet, D. W. Evans, and H. Stephenson, Anticoagulants in congestive heart failure, Brit Med J, 2:866(1966).PubMedCrossRefGoogle Scholar
  9. 9.
    W. W. Coon, and P. W. Willis III, Thromboembolic complications during anticoagulant therapy, Arch Surg 105:209(1972).PubMedCrossRefGoogle Scholar
  10. 10.
    The Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly, JAMA, 256:70(1986).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Stanford Wessler
    • 1
  1. 1.Department of MedicineNew York University School of MedicineNew YorkUSA

Personalised recommendations